Cui Aili, Zhang Yan, Zhu Zhen, Wang Huiling, Mao Naiying, Song Jinhua, Xu Wenbo
WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155, Changbai Road, Changping District, Beijing 102206, People's Republic of China.
WHO WPRO Regional Reference Laboratory of Measles/Rubella and NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155, Changbai Road, Changping District, Beijing 102206, People's Republic of China.
Vaccine. 2020 May 8;38(22):3832-3838. doi: 10.1016/j.vaccine.2020.03.049. Epub 2020 Apr 10.
Measles incidence has decreased dramatically in China due to the implement of measles-containing vaccine (MCV). However, a measles epidemic caused resurgence recently, even among vaccinated individuals. To evaluate the effectiveness of current immunization programs and discuss initiatives for the next step in measles elimination in mainland China, the characteristics of 121,969 laboratory-confirmed measles cases reported in the measles surveillance system (MSS) during 2014-2018 were analyzed according to the vaccination status of the cases in this study. Children under 2 years of age without MCV vaccination (44,424, 36.42% of all cases) and adults over 20 years of age with an unknown vaccination history (37,564, 30.80% of all cases) accounted for the majority of measles cases from 2014 to 2018. 42,425 (34.78%) of the 77,384 cases with available vaccination information were categorized as programmatically preventable. 38,840 (91.55%) of the 42,425 cases were aged ≥8 months without the MCV vaccination history. 34,959 (28.66%) cases were categorized as programmatically non-preventable, of whom 22,611 (64.68%) were too young to receive their first MCV dose, 6857 (19.61%) received their first dose and were too young to receive their second dose, 5491 (15.71%) received at least two doses of MCV. 15,933 (13.06%) of the 121,969 cases had a history of MCV vaccination. Measles virus infection in cases with an MCV vaccination history mainly occurred within the first month after MCV vaccination, especially in those who received a one-dose measles vaccination. MCV vaccination could reduce the frequencies of clinical symptoms and complications of measles cases. Our study confirmed that the current measles immunization programs used in mainland China is effective in reducing the measles incidence in China. Unvaccinated infants/children aged 8-23 months and high risk susceptible adults over 20 years of age with unknown vaccination histories should be the focus groups of measles immunization activities in China in the future.
由于含麻疹疫苗(MCV)的实施,中国的麻疹发病率已大幅下降。然而,最近麻疹疫情出现反弹,甚至在已接种疫苗的人群中也有发生。为评估当前免疫规划的效果,并讨论中国大陆下一步消除麻疹的举措,本研究根据2014 - 2018年麻疹监测系统(MSS)报告的121,969例实验室确诊麻疹病例的疫苗接种状况,对其特征进行了分析。2014年至2018年的麻疹病例中,大部分是2岁以下未接种MCV的儿童(44,424例,占所有病例的36.42%)和20岁以上疫苗接种史不明的成年人(37,564例,占所有病例的30.80%)。在77,384例有可用疫苗接种信息的病例中,42,425例(34.78%)被归类为按规划可预防的病例。42,425例病例中的38,840例(91.55%)年龄≥8个月且无MCV疫苗接种史。34,959例(28.66%)病例被归类为按规划不可预防的病例,其中22,611例(64.68%)年龄太小无法接种第一剂MCV,6857例(19.61%)已接种第一剂但年龄太小无法接种第二剂,5491例(15.71%)至少接种了两剂MCV。121,969例病例中有15,933例(13.06%)有MCV疫苗接种史。有MCV疫苗接种史的病例中,麻疹病毒感染主要发生在接种MCV后的第一个月内,尤其是那些仅接种一剂麻疹疫苗的人。MCV疫苗接种可降低麻疹病例的临床症状和并发症发生率。我们的研究证实,中国大陆目前使用的麻疹免疫规划在降低中国麻疹发病率方面是有效的。8 - 23个月未接种疫苗的婴儿/儿童以及20岁以上疫苗接种史不明的高风险易感成年人应是中国未来麻疹免疫活动的重点人群。